19:31:25 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaMid Cap Stockholm
Cantargia är ett läkemedelsbolag. Idag återfinns specialisering mot utveckling av antikroppsläkemedel som används vid behandling av leukemi samt övriga cancersjukdomar som lung- och pankreascancer. Bolagets målsättning är att utveckla, sälja och licensiera läkemedelskandidater till bolag verksamma inom nämnt arbetsområde. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Lund.


2024-02-22 Bokslutskommuniké 2023
2023-11-10 Kvartalsrapport 2023-Q3
2023-08-22 Kvartalsrapport 2023-Q2
2023-05-23 Årsstämma 2023
2023-05-23 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-30 Kvartalsrapport 2022-Q2
2022-07-21 Extra Bolagsstämma 2022
2022-05-24 Ordinarie utdelning CANTA 0.00 SEK
2022-05-23 Kvartalsrapport 2022-Q1
2022-05-23 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-27 Ordinarie utdelning CANTA 0.00 SEK
2021-05-26 Kvartalsrapport 2021-Q1
2021-05-26 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-10-13 Extra Bolagsstämma 2020
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-28 Ordinarie utdelning CANTA 0.00 SEK
2020-05-27 Kvartalsrapport 2020-Q1
2020-05-27 Årsstämma 2020
2020-02-27 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-28 Ordinarie utdelning CANTA 0.00 SEK
2019-05-27 Årsstämma 2019
2019-05-27 Kvartalsrapport 2019-Q1
2019-02-27 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-06-01 Ordinarie utdelning CANTA 0.00 SEK
2018-05-31 Årsstämma 2018
2018-05-15 Kvartalsrapport 2018-Q1
2018-02-28 Bokslutskommuniké 2017
2017-11-15 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-31 Ordinarie utdelning CANTA 0.00 SEK
2017-05-30 Årsstämma 2017
2017-05-15 Kvartalsrapport 2017-Q1
2017-03-15 Bokslutskommuniké 2016
2017-01-16 Extra Bolagsstämma 2017
2016-11-21 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-25 Årsstämma 2016
2016-05-16 Kvartalsrapport 2016-Q1
2016-03-02 Ordinarie utdelning CANTA 0.00 SEK
2016-03-01 Bokslutskommuniké 2015
2015-11-17 Kvartalsrapport 2015-Q3
2015-08-25 Kvartalsrapport 2015-Q2
2015-05-19 Kvartalsrapport 2015-Q1
2015-03-03 Bokslutskommuniké 2014
2022-07-04 14:00:00
  • Cantargia rights issue webcast to take place on July 7, 2022 at 2:00 PM CET/8:00 AM ET
  • Recently presented positive clinical results in non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC)
  • Capital to advance development in NSCLC and PDAC trials and other opportunities

Cantargia AB (Cantargia AB; Nasdaq Stockholm: CANTA) today issued an invitation to attend a webcast on its recently announced fully covered rights issue. The text of the invitation is as follows:

Cantargia invites you to register for and attend an online briefing (webcast) on Cantargia's recently announced fully covered rights issue intended to raise approximately SEK 250 million in additional capital.

Cantargia's lead asset, nadunolimab (CAN04), has shown very promising efficacy results in phase IIa studies in over 70 PDAC patients as well as 30 NSCLC patients, as shared recently with scientific and clinical colleagues at the American Society for Clinical Oncology (ASCO) Annual Meeting 2022. As described in Cantargia's announcement of June 21, 2022, the principal and immediate reasons for raising primary proceeds are to enable Cantargia to build on the positive data obtained in PDAC and NSCLC and progress the late-stage clinical development of nadunolimab.

To obtain regulatory approval to market nadunolimab, Cantargia is required to run larger, comparative phase II/III trials. Our goal with the rights issue is to secure financing for:
  • Preparation of a randomized trial in patients with non-squamous NSCLC, to start in 2023
  • The phase II/III Precision Promise℠ trial in PDAC in collaboration with PanCAN, carried out in leading clinical US centers
  • Advancing nadunolimab in select second wave indication(s) currently under assessment, after prioritization in 2022

The webcast will last approximately 30 minutes and will include short presentations from Cantargia's CEO, Göran Forsberg and Cantargia's CFO, Bengt Jöndell. There will be an opportunity for shareholders to ask questions and seek clarifications from the Cantargia team.

Registration information
Shareholders or other interested parties are required to register in advance for the webcast here (https://lifesci.rampard.com/WebcastingAppv5/Events/eventsDispatcher.jsp?Y2lk=MTk2Mg==). For those who are unable to listen at this time, a replay of the call will be available by clicking here (https://lifesci.rampard.com/WebcastingAppv5/Events/Registration/registration.jsp?Y2lk=MTk2Mg==&Y2lk=MTk2Mg==). If you would like to ask a question during the live Q&A, please submit your request to questions@lifesciadvisors.com.

If you have any questions on the webcast or on the EGM, please contact our Investor Relations team by e-mail at info@cantargia.com.

For further information, please contact:
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

This information was submitted for publication, at 14.00 CET on 4 July 2022.

About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The lead project, the antibody nadunolimab (CAN04), is being studied clinically in combination with chemotherapy or immune therapy in a series of clinical studies - CANFOUR, CIRIFOUR, CAPAFOUR, CESTAFOUR and TRIFOUR - with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second project, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at https://cantargia.com/en/